• 48 Altered gut microbiota in stable patients with cystic fibrosis (CF) compared to controls and its relationship with intravenous (IV) antibiotic usage and lung function

      Burke, D.G.; Fouhy, Fiona; Rea, Mary; Harrison, M.J.; STANTON, CATHERINE; O’Sullivan, Orla; Murphy, D. M.; O'Callaghan, G. P.; Eustace, J. A.; Shanahan, F.; et al. (Elsevier, 2015-06-05)
      Objective CF is associated with altered digestive function and thus nutrient availability for gut microbes in addition to altered gut microbiota, compared with healthy controls. Equally intensive antibiotic and nutritional therapy may further compound this. We present results from the largest CF gut microbiota study to date.
    • A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis

      Fouhy, Fiona; Ronan, N. J.; O'Sullivan, Orla; McCarthy, Y.; Walsh, Aaron M.; Murphy, D.M.; Daly, M.; Flanagan, E. T.; Fleming, C.; McCarthy, M.; et al. (Nature Publishing Group, 2017-07-27)
      Cystic Fibrosis (CF) and its treatment result in an altered gut microbiota composition compared to non-CF controls. However, the impact of this on gut microbiota functionality has not been extensively characterised. Our aim was to conduct a proof-of-principle study to investigate if measurable changes in gut microbiota functionality occur in adult CF patients compared to controls. Metagenomic DNA was extracted from faecal samples from six CF patients and six non-CF controls and shotgun metagenomic sequencing was performed on the MiSeq platform. Metabolomic analysis using gas chromatography-mass spectrometry was conducted on faecal water. The gut microbiota of the CF group was significantly different compared to the non-CF controls, with significantly increased Firmicutes and decreased Bacteroidetes. Functionality was altered, with higher pathway abundances and gene families involved in lipid (e.g. PWY 6284 unsaturated fatty acid biosynthesis (p = 0.016)) and xenobiotic metabolism (e.g. PWY-5430 meta-cleavage pathway of aromatic compounds (p = 0.004)) in CF patients compared to the controls. Significant differences in metabolites occurred between the two groups. This proof-of-principle study demonstrates that measurable changes in gut microbiota functionality occur in CF patients compared to controls. Larger studies are thus needed to interrogate this further.
    • WS16.1 Clinical Outcomes of Real-World Kalydeco (CORK) study – Investigating the impact of CFTR potentiation on the intestinal microbiota, exocrine pancreatic function and intestinal inflammation prospectively over 12 months

      Deane, Jennifer; Ronan, N. J.; O'Callaghan, G. P.; Fouhy, Fiona; Rea, Mary; O'Sullivan, Orla; Hill, C. J.; Shanahan, F.; Ross, R Paul; McCarthy, M.; et al. (Elsevier, 2015-06-05)
      Objectives Ivacaftor is effective in the treatment of patients with CF and the G551D gating mutation. We present faecal analysis results of the CORK cohort, a single-centre, adult (n = 20), prospective, longitudinal study of G551D clinical responders (median follow-up 12 months), examining the gut microbiota, exocrine pancreatic function and intestinal inflammation on a 3 monthly basis after commencing treatment.